Watson Laboratories, Inc.

Watson Laboratories, Inc. is a U.S. generic-drug manufacturer, incorporated in 1985 as the operating entity founded by Allen Chao and David Hsia (the business launched in 1984 as Watson Pharmaceuticals). Its original corporate headquarters were in Corona, California; corporate offices later moved to Parsippany, New Jersey. Watson is no longer independent: after merging with Actavis (2012) and renaming itself Actavis, Inc. (2013), it passed through Actavis plc/Allergan plc and was sold to Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA) in the 2016 Allergan generics deal. Court filings and Rule 7.1 disclosures confirm Watson Laboratories is an indirect wholly-owned Teva subsidiary, with principal executive offices at 400 Interpace Parkway, Parsippany, NJ. No standalone employee or revenue figures are published today; historical filings put Watson at roughly 5,600 employees and ~$2.5B revenue (2007), third- to fifth-largest U.S. generic manufacturer at the time.

Operations. Watson develops, manufactures and markets generic (off-patent) prescription pharmaceuticals via abbreviated new drug applications (ANDAs) — oral solids, transdermal patches, and one of the industry's larger generic oral-contraceptive lines — alongside a smaller branded portfolio (e.g., Oxytrol, Androderm, Ferrlecit) and the Anda distribution business. Manufacturing and R&D sites have included Corona, CA; Salt Lake City, UT; and Davie, FL. It is an operating company, not an NPE.

Litigation posture. The tracked dockets show a classic two-way ANDA litigant: as defendant in Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc. et al. (D. Del., 1:19-cv-00317, filed Feb. 2019, terminated Nov. 2020), and as co-petitioner with Teva in the parallel PTAB proceeding against Merck. Suits are in the District of Delaware, not an NPE-style plaintiff venue, and Watson has never appeared as a volume patent plaintiff.

Context. The Merck dispute centered on Orange Book patents covering sitagliptin phosphate (Januvia); Teva/Watson's PTAB petition challenged the '708 patent as a "me-too" filing following Mylan's instituted IPR. Watson has also been a frequent defendant in Hatch-Waxman suits (e.g., UCB, Indivior/Suboxone, Bayer vardenafil, Sanofi) and, separately, a defendant in opioid-related public-nuisance and antitrust matters naming former Actavis/Teva entities.